Sabril
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Adult Refractory Complex Partial Seizures
Conditions
Adult Refractory Complex Partial Seizures
Trial Timeline
Dec 1, 2010 โ May 1, 2015
NCT ID
NCT01278173About Sabril
Sabril is a approved stage product being developed by Lundbeck for Adult Refractory Complex Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01278173. Target conditions include Adult Refractory Complex Partial Seizures.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01278173 | Approved | Completed |
Competing Products
20 competing products in Adult Refractory Complex Partial Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 + sotorasib | BridgeBio Pharma | Phase 1 | 30 |
| Daridorexant + Placebo | Idorsia | Phase 1 | 28 |
| SON-1010 (IL12-FHAB) | Sonnet BioTherapeutics | Phase 1 | 28 |
| Somatropin | Eli Lilly | Phase 3 | 77 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Pegilodecakin | Eli Lilly | Phase 1 | 33 |
| eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Lazertinib(G001) + Lazertinib(G002) | Yuhan | Phase 1 | 33 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |
| Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride | Eisai | Phase 1 | 33 |